Grant: Project Grant

When prostate cancers progress to the therapy-resistant stage, there is no cure. Although hormonal therapies and chemotherapies can inhibit tumor progression temporarily, many cancer cells change their identities to survive these therapies and re-populate causing tumors to return. New findings from our lab showed that the Lin28b gene enables tumor cells to alter their cell identity and promotes prostate tumors to develop therapy resistance. We will therefore investigate how Lin28b exerts such cellular functions to survive anticancer therapies. We will also design small molecule inhibitors as a potential therapy for prostate cancer progression.